Stock Screener App

Frei -

Installieren

1.36

3.03% 0.04

Adc Therapeutics Sa (ADCT)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript - AOL.com

ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Following a 56% Decline Over Last Year, Recent Gains May Please ADC Therapeutics SA (NYSE:ADCT) Institutional Owners - 富途牛牛

Guggenheim cuts ADC Therapeutics stock price target on FDA concerns By Investing.com - Investing.com South Africa

symbol__ Stock Quote Price and Forecast - CNN

Antibody-Drug Conjugates (ADC) Market Set to Witness Significant - The National Law Review

ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook - Yahoo Finance

ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - MarketBeat

Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com

ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance

ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180 - TradingKey

ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada

ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance

ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat

ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat

ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com

ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade

Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria

ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView

ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com

ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - Quiver Quantitative

ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - Yahoo Finance

Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - GuruFocus

ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView

ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

ADC Therapeutics SA (ADCT) Stock News Today - TradingKey

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - Morningstar

ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday - MarketBeat

BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan

ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat

ADC Therapeutics SA (ADCT) Income Statement - TradingKey

ADCT|ADC Therapeutics SA|Price:1.010|Chg%:-0.050 - TradingKey

ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

ADCT|ADC Therapeutics SA|Price:1.139|Chg%:-0.000 - TradingKey

ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey

ADC Therapeutics SA (ADCT) Cash Flow - TradingKey

ADC Therapeutics SA (ADCT) Balance Sheet - TradingKey

ADC Therapeutics (ADCT) Drops 5.7% as Stock Nears Critical SupportCovered Call ETF - vinanet.vn

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus

ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de

ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de

ADC Therapeutics (ADCT) Rises Modestly, Testing Key Resistance Near $1.33Zigzag Correction - Vinanet

ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - MarketBeat

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review

ADC Therapeutics (ADCT) Holds Steady at $1.35 as Key Support and Resistance Levels NarrowVol Target Rebalance - vinanet.vn

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review

ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et

ALKS

$46.10

1.66%

RDY

$11.97

0.50%

ELAN

$24.50

0.33%

NBIX

$155.64

1.71%

VTRS

$16.88

0.35%

UTHR

$487.61

0.54%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters